Riskpilot← Back to searchSign inGet full accessMODERNA NORWAY AS
ASActiveOrg 828882082Bryggegata 6, 0250 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20221 employees
Revenue 2024
NOK 3,8M
+5% vs 2023
EBITDA margin
4.7%
-4% vs 2023
Equity ratio
59.8%
Financial strength
Net profit 2024
NOK -16K
-106% vs 2023
| Revenue | NOK 3,8M | +5% |
| EBITDA | NOK 177K | -4% |
| Net profit | NOK -16K | -106% |
| Total assets | NOK 5M | +16% |
| Equity | NOK 3M | -1% |
| Employees | 1 | — |
Legal name
MODERNA NORWAY AS
Org number
828882082
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. mars 2022
Share capital
NOK 33 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Drive forretninger med legemidler, inkludert import, promotering, markedsføring og distribusjon av helse- og farmasøytiske produkter, inkludert mrna-medisiner, samt andre relaterte aktiviteter.
Address
Bryggegata 6, 0250 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 3 620 | 3 806 |
| Staff expenses | −0 | −1 715 | −2 918 |
| EBITDA | −200 | 184 | 177 |
| Depreciation & amort. | −0 | −5 | −10 |
| EBIT | −200 | 179 | 168 |
| Net financials | −263 | 227 | −5 |
| Profit before tax | −463 | 407 | 163 |
| Tax | −103 | 131 | 178 |
| Net profit | −360 | 276 | −16 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 2 940 | 4 348 | 5 030 |
| Equity | 2 748 | 3 024 | 3 009 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 192 | 1 324 | 2 022 |
| Total debt | 192 | 1 324 | 2 022 |
EBITDA margin
4.7%
This company
15.8%
Market median
-70% vs market
20222024
Equity ratio
59.8%
This company
38.2%
Market median
+57% vs market
20222024
Return on equity
-0.5%
This company
18.4%
Market median
-103% vs market
20222024
Net profit margin
-0.4%
This company
8.1%
Market median
-105% vs market
20222024
Asset turnover
0.76×
This company
1.12×
Market median
-32% vs market
20222024
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SK Contact Person | Contact Person | 2024 |
| Former (2) | ||
JM Contact Person | Contact Person | 2023 – 2024 |
SK Contact Person | Contact Person | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairman | 2026 | |
| Chairman | 2022 | |
| Board of Directors | 2023 | |
| Board of Directors | 2026 | |
| Board of Directors | 2026 | |
| Former (2) | ||
| Board of Directors | 2022 – 2023 | |
| Chairman | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Moderna Biotech Uk Limited | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MODERNA NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Julie Marie Flom | Contact Person | 0 companies |
| Sumeet Kaur Kumra | Contact Person | 0 companies |
| Sumeet Kaur Uppal | Contact Person | 0 companies |
| Jed Davidson Larkin | Chairman | 0 companies |
| Brian Taylor Sandstrom | Chairman | 0 companies |
| Andreas William Hennyng | Board of Directors | 0 companies |
| Kristian Brekke Djuve | Chairman | 0 companies |
| John Erik Mattias Bankel | Board of Directors | 0 companies |
| Chantal Sylvie Le Quellec | Board of Directors | 0 companies |
| Lisa Anne Kinsella | Board of Directors | 0 companies |